{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-070415","form_type":"8-K","ticker":"RVRC","cik":"0001839140","company_name":"Revium Rx.","filed_at":"2026-06-22T13:42:07+00:00","discovered_at":"2026-06-22T13:43:00.267315+00:00","generated_at":"2026-06-22T13:43:14.923987+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Revium Rx COO, President and Director Inna Martin resigns due to differences in expectations","bullets":["Inna Martin resigned as Director, COO, and President effective June 16, 2026, due to differences in expectations with the company.","Separation agreement: employment and consultancy with Revium Ltd. ends Sep 10, 2026; vested stock option exercise period extended to Sep 30, 2028 for up to 2,440,000 shares.","Shares and options subject to sale restrictions per Separation Agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-070415","json":"https://secwatch.observer/filing/0001213900-26-070415.json","markdown":"https://secwatch.observer/filing/0001213900-26-070415.md","text":"https://secwatch.observer/filing/0001213900-26-070415.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1839140/000121390026070415/0001213900-26-070415-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1839140/000121390026070415/ea0295431-8k_revium.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T13:43:14.923987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}